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creativecommons.org/licenses/by-nc-nd/Abstract Background: New technologies and techniques in radiation oncology and imaging
offer opportunities to enhance the benefit of loco-regional treatments, expand treatment to
new patient populations such as those with oligometastatic disease and decrease normal tissue
toxicity. Furthermore, novel agents have become available which may be combined with radi-
ation therapy, and identification of radiation-related biomarkers can be studied to refine treat-
ment prescriptions. Finally, the use of artificial intelligence (AI) capabilities may also improve
treatment quality assurance or the ease with which radiation dosing is prescribed. All of these
potential advances present both opportunities and challenges for academic clinical researchers.
Methods: Recently, the European Organisation for Research and Treatment of Cancer ad-
dressed these topics in a meeting of multiple stakeholders from Europe and North America.
The following five themes radiobiology-based biomarkers, new technologies e particularly
proton beam therapy, combination systemic and radiation therapy, management ofganisation for Research and Treatment of Cancer, Avenue Mounier 83/11, B - 1200, Brussels, Belgium.
c.org (D. Lacombe).
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G. Thomas et al. / European Journal of Cancer 131 (2020) 76e88 77oligometastatic disease and AI opportunities in radiation oncology were discussed in a State of
Science format to define key controversies, unanswered questions and propose clinical trial
priorities for development.
Conclusions: Priorities for clinical trials implementing new science and technologies have been
defined. Solutions to integrate the multidimensional complexity of data have been explored.
New types of platforms and partnerships can support innovative approaches for clinical
research in radiation oncology.
ª 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The field of cancer therapy has seen enormous changes
within the last two decades. While much interest has
been directed to the emergence of novel systemic ther-
apies which capitalise on evolving biological knowledge
of malignancy, there have also been substantial changes
in technologies and techniques relevant to radiation and
surgical treatments of cancer.
While the regulatory environment requires that new
drugs undergo clinical trial evaluation before marketing,
the adoption of new technologies is not as constrained.
Indeed, to truly evaluate these novel approaches, there
must be some degree of training and adoption by health
sciences centres to enable clinical trials to take place. As
a result, randomised clinical trials addressing the clinical
benefit of novel radiation oncology approaches or de-
livery technologies have been limited. Often new tech-
nology simply replaces old based on empiricism or
theoretical advantages, often explained by the duration
of prospective clinical research not being competitive
with the speed of constantly advancing technologies [1].
That being said, academic cancer cooperative groups are
ideally suited to provide the infrastructure and access to
larger patient populations to support investigation and
the clinical trials necessary to rigorously understand the
impact of such innovations on outcomes of importance
in cancer (survival, toxicity, quality of life, patient-
reported outcomes and, increasingly, value for money).
The European Organisation for Research and
Treatment of Cancer (EORTC) is one of the oldest or-
ganisations conducting such critical research. The Ra-
diation Oncology Group of the EORTC has conducted
trials that have shaped practice in breast, lung, head and
neck and Genito-Urinary (GU) cancers to name but a
few. In addition, EORTC Disease Oriented Groups
have thriving radiation oncology members engaged in
trial development and conduct.
The rapidly changing landscape of radiation
oncology including the emergence of highly conformal
radiation techniques, particle therapies, new approaches
to management of localised and oligometastatic disease,
new discoveries in biology, the rise of artificial intelli-
gence (AI) imagingebased algorithms and emergence ofnovel drugs available for combination with radiation
treatment led the EORTC to sponsor a ‘State of Science’
meeting to update knowledge and explore research op-
portunities in radiation oncology. Radiation oncologists
from EORTC, the European Society for Radiotherapy
and Oncology (ESTRO), Canada and the United States,
as well as researchers in particle therapy, radiation
biology, immunology, patient-reported outcomes and
trial methodology were gathered in September 2018 to
review current available evidence supporting practice in
various areas, discuss and debate where clinical research
should be directed to improve cancer outcomes and to
create a menu of priority radiation oncologyebased
clinical trial questions for further development.
A planning committee created an agenda of priority
themes for discussion over a 2-day period, and invited
attendees were balanced across therapeutics areas,
expertise and European countries (Appendix I). This
manuscript summarises key points in the discussion and
recommended priority questions and areas for research
for study by the EORTC and other organisations.2. Biology-guided dosing in radiation therapy: where do
we stand?
2.1. Current state
Over the last decades, major developments in the use of
radiation to treat cancer have been focused on the
physically accurate delivery of radiation therapy. This
has resulted in the ability to conform radiation dose very
precisely to the target of interest thus sparing, as much
as possible, surrounding adjacent normal tissues to
reduce attendant toxicities. While radiation dosing has
become physically accurate, it is lacking in biological
precision related to what is known, or yet to be
discovered, with respect to specific individual tumour
and normal tissue response to radiation. ‘Personalized
radiation therapy’ has, to date, been defined anatomi-
cally rather than incorporating the direct or surrogate
biomarkers that predict the sensitivity of the tumour
and normal tissues [2].
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are more likely to respond or be eradicated by max-
imising the radiation dose used. However emerging and
validated clinical markers and other evidence across
diverse tumours have identified that the previous dose
paradigm is too broad and inaccurate to apply to all
tumour types and patients. This section of the workshop
focused on which biology-based predictive biomarkers
are validated and ready for evaluation in clinical trials to
tailor treatment.2.2. Questions ready for clinical trial evaluation
Table 1 shows the current landscape of predictive bio-
markers to guide radiation therapy. As shown, these are
in various stages of validation and clinical development.
Both measures of radiosensitivity and hypoxia would
appear to be sufficiently validated to derive level I evi-
dence for their use in tailored dose selection in appro-
priate subpopulations. Two of the most promising
predictive biomarkers use RNA expression signatures to
classify subpopulations of sensitive and resistant tu-
mours of a given histopathologic type:
a The radiation sensitivity index (RSI-GARD (Genomic
Adjusted Radiation Dose)) has been validated across mul-
tiple disease sites including different end-points for evalu-
ation. In general, the RSI is bimodal which implies that the
delivery of a higher dose of radiation does not necessarily
guarantee a greater anti-tumour effect. Indeed, the biolog-
ical effect may change. For certain patients, a lower than
conventional dose could be adequate for tumour control,
and for others, even a higher dose would be inadequate.
b The importance of hypoxia is well known in governing
response to radiation treatment and has been validated as a
predictive biomarker for many tumours (Table 1). Tumour
hypoxia can be identified by various measures including theTable 1
Predictive biomarkers for radiation sensitivity.
Discovery
Radiosensitivity RSI-GARD
RNA Sig
Hypoxia RNA Sig PET/MRI
Genomic PGA/MTs
Proteomic P16
MRE11
MCMT
Immune (X)
Imaging PET FDG
PET MISO
CBCT
Machine learning Radiomics (X)
Normal tissue RILA
Foray
Models  SNPs
Radiomics
(X)
(X)
PGA/MT, Power for Genomic Association Analysis; P16, MRE11, and M
PET-MISO, PET 18F Miso; CBCT, cone beam computed tomography; RRNA signature (validated) or by hypoxia focused Positron
Emission Tomography (PET) or Magnetic Resonance Im-
aging (MRI) imaging (requires validation).
RSI-GARD and hypoxia markers are ready to be
evaluated directly in stratifying tumours for studies in
which patients may be randomised to treatment with
different radiation doses depending on these predictive
biomarkers. Two major types of questions are ready for
biology-driven radiation clinical research based on the
aforementioned ones and were developed and discussed
in the State of Science meeting:
a Randomized trials focused on improving in local control/
survival
o Example e currently curatively treated cancers in stage
IIIa patients with Non Small Cell Lung Cancer (NSCLC)
would be randomised to standard dose radiation or to
tailored radiation dosing (þ/ chemotherapy) based on
their RSI-GARD and hypoxia signatures. The end-points
would include both tumour and toxicity outcomes with
the hypothesis being that signature designed treatment
would improve tumour outcomes. Specific tumour sites
discussed as suitable for this type of trial included not
only NSCLC but also HPV-negative head and neck,
locally advanced prostate, oesophageal and endometrial
cancers. Similar studies could also be relevant for rela-
tively radioresistant tumours where radiation is part of a
standard of care (e.g. pancreatic adenocarcinoma, glio-
blastoma and mesothelioma).
b Randomised trials designed to refine selection of patients
for chemoradiation vs. surgery to minimise normal tissue
toxicity.
o Example e Muscle invasive bladder cancer (OR locally
advanced rectal cancer). Patients would be randomised
between standard approach of chemoradiation or surgery
based on current clinical decision rules vs. a RSI-GARDValidation Level 1 evidence
Y (many tumours) [3]
Y (many tumours) [4e6] Y (bladder; head
and neck cancer) [4,7]
(X) N
(X)
(X)
(X)
N
N
(X)
(X)
(X)
N
N
Y (breast [8]; prostate [9]) N
CMT are gene coding proteins; PET-FDG, PET-Flurodeoxuglucose;
ILA, radiation-induced CD8 T-lymphocyte apoptosis.
Table 2
Examples of ongoing randomised phase III trials of proton vs. photon therapy.
Tumour type Study arms Sample size Primary end-point
MDACC Head and
neck cancer (US) NCT01893307
Oropharyngeal cancer  Intensity-modulated proton
beam therapy (IMPT)
 Intensity-modulated photon
therapy (IMRT)
360 Toxicity
NRG
Oesophageal cancer
(US) NCT03801876
Oesophageal cancer  Proton Beam therapy
paclitaxel
Carboplatin Oesophagectomy
 Intensity-modulated photon
therapy (IMRT) paclitaxel
Carboplatin oesophagectomy
300 Overall Survival
RTOG Lung cancer
(US) NCT01993810
NSCLC  Proton beam therapy with
concurrent and adjuvant chemo
 Photon beam therapy with
concurrent and
adjuvant chemo
330 Overall Survival Cardiac
toxicity and Lymphopenia
NRG Liver cancer
(US) NCT03186898
Hepatocellular cancer  Proton beam therapy
 Photon beam therapy
186 Overall Survival
RADCOMP (US)
NCT02603341
Post-surgical, locally
advanced breast cancer
 Proton beam therapy
 Photon beam therapy
1278 Toxicity (Cardiac events)
PARTIQoL (US)
NCT01617161
Prostate cancer; low
intermediate risk
 Proton beam Therapy
 Intensity-modulated photon
therapy (IMRT)
400 Toxicity (bowel toxicity)
PAROS (Heidelberg)
NCT04083937
Prostate  Hypofractionated radiotherapy
with photons
 Hypofractionated radiotherapy
with protons
 Normofractionated
radiotherapy with photons
897 QoL (bowel toxicity)
MDACC, MDAnderson Cancer Center NRG: each letter is the first of the followings National Surgical Adjuvant Breast and Bowel Project (NSABP),
the Radiation Therapy Oncology Group (RTOG), and the Gynecologic Oncology Group (GOG); RTOG, the Radiation Therapy Oncology Group;
RADCOMP, Radiotherapy Comparative Effectiveness; PARTIQoL, Prostate Advanced Radiation Technologies Investigating Quality of Life;
PAROS, Prostate Cancer Patients Treated With Alternative Radiation Oncology Strategies; NSCLC, Non Small Cell Lung Cancer.
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cancer example, patients on the experimental arm would
be assigned surgery when RSI-GARD score is high and
low RSI-GARD score patients would have bladder pre-
serving chemoradiation.
Addressing questions such as those outlined would
clarify how best to incorporate these predictive bio-
markers into standard practice and decision-making. An
increasing issue for prediction is the use of combined
modality treatments using radiation therapy in combi-
nation with chemotherapy, molecular targeted agents or
immunotherapy (refer in the following paragraphs). A
‘radiotherapy only’ signature may not translate in these
settings.
3. How can we address new technologies in the therapeutic
armamentarium for optimised patient care/cure e focus
on proton therapy
3.1. Current state
The second theme discussed at the State of Science
meeting addressed the question of how new radiationtechnologies should be researched and incorporated into
the therapeutic armamentarium to optimise patient care
and cure. Currently many new technologies have been
incorporated into cancer therapy with only modest
levels of clinical evidence for their benefit [1]. The new
technologies available include but are not limited to
intensity-modulated photon therapy, image guided
radiotherapy (IGRT), stereotactic body radiotherapy
(SBRT), magnetic resonance-linac (MR-linac) and par-
ticle therapies.
The main interest of the participants at the State
of Science was on the use of proton therapy so that
was the focus of the discussion. This therapy requires
substantial investment and infrastructure and is being
adopted in many countries because of the preclinical
experimental data that proton therapy can reduce
normal tissue toxicity [10]. To date, most available
data have been based on physical modelling of pro-
ton vs. photon beams and/or observational series in
the clinic with very limited randomised clinical data
identifying whether or not its theoretical benefits are
being realised [11e14]. There are several tumour
types where the theoretical advantages of proton
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are not limited to childhood brain and spinal cord
tumours [15], as well as base of skull tumours, head
and neck cancers, uveal tumours and other paediatric
cancers.
3.2. Questions ready for clinical trial evaluation
A variety of considerations were discussed in the context
of trial designs of proton therapy. These included
innovative trial methodologies and use of end-points
relevant to patients including quality of life, toxicity and
disease outcomes. Given the higher capital and opera-
tional cost of this innovative technology, it was
considered that health economic parameters must also
be incorporated [16]. In addition, translational research
questions including biomarkers with radiomics and ge-
netic signatures should be part of such trials. Finally, it
was clear that clinical trials of new technologies must
always be accompanied by rigorous quality assurance.
As noted previously, the theoretical favourable ther-
apeutic ratio of proton vs. photon therapy needs to be
confirmed in phase III randomised trials. While this
level of evidence is not yet available and several
randomised trials are ongoing (for examples, refer Table
2, compiled after the meeting for this report), some
centres are currently treating patients with protons
outside of randomised clinical trials, and it will be
important to set up prospective collection of high-
quality data on the toxicity and efficacy outcomes for
those patients through the European Proton Therapy
Network (www.estro.org/Science/EPTN).
During the State of Science discussions, two major
directions for clinical research studies were agreed: The
first was to determine whether protons can reduce
radiotherapy (RT)-induced morbidity, while maintain-
ing the same or better tumour control/survival (normal
tissue complication probability [NTCP] domain). The
second was whether proton therapy can improve
tumour control and survival (tumour control
probability [TCP] domain) in disease sites where the
outcome of traditional photon radiation therapy is poor
or alternatively where radiation is not in use.
3.2.1. Reduction of RT-induced morbidity
There was strong support to develop and validate,
through clinical trials, the use of an NTCP model to
predict in individual patients the expected toxicity from
proton vs. photon treatment and, based on this, select
the preferred type of radiation.
A benefit of protons versus photons in terms of lower
rates of radiation-induced toxicity with similar local con-
trol can only be obtained when 3 conditions are met: (1)
The target dose should be biologically equivalent; (2) The
dose to the most relevant organs at risk should be lower(DDose) and (3) ThisDDose is expected to translate into a
lower rate of toxicity ((DNTCP) For example, in head and
neck cancer, relevant toxicities (dysphagia, xerostomia,
tube feeding dependence, oral mucositis, salivary inflam-
mation and so on) would be predicted from the planned
dose received for both the photon and proton plan for the
same patient [17]. If no or minimal benefit were to be ex-
pected in terms of the modelled toxicity for protons over
photons, the patient would be assigned to photon therapy.
If there were a substantial reduction in toxicity predicted
with protons, the patient would be assigned to proton
therapy. A trial to validate (and modify if needed) the
NTCP model would be important because, if validated, it
could be deployed in clinical decision-making to select
patients for proton therapy who might be spared sub-
stantial toxicity.
Validation of the model requires prospective clinical
studies and is a multistep process. As a first step, ob-
servations of patients treated with both photons and
protons should allow the subsequent refinement of the
model predictions to match observed outcomes; the
second step would be a classic Randomised Clinical
Trial (RCT) randomising those with a ‘meaningful’
predicted reduction in toxicity to protons vs. photons. A
challenge will be to determine what level of ‘toxicity’
reduction would make the new technology an acceptable
standard in terms of clinical relevance and/or costs.
Patient input on reported toxicities will be an important
end-point to be incorporated.
Potential tumour types for these trials having a primary
goal of reducing morbidity include head and neck cancer,
stage IIIC endometrial cancer and low-grade glioma.
3.2.2. Improving tumour control
On the other side of the therapeutic ratio, there is in-
terest in determining if proton therapy and the theo-
retical ability to safely increase radiation dose to target
using this modality could lead to improved tumour
control compared with standard photon therapy.
Tumour types where normal tissue toxicity limits de-
livery of high dose radiation are ones where this could
be investigated and include oesophageal cancer, glio-
blastoma, HPV-negative head and neck cancer, sarcoma
and chordoma/chondrosarcoma. The appropriate
randomised trial design should include standard of care
(radiation or chemoradiation) with photons in one arm,
with escalated proton dosing in the experimental arm to
an approximate equivalent toxicity. Key end-points
would be overall survival, tumour control and toxicity.
4. How artificial intelligence may change practice in
radiation oncology
AI is the theory and the development of computer sys-
tems that are able to perform tasks at a level comparable
Table 3
Randomised phase II trials of local ablative treatment (SBRT) vs control.
Citation Tumour type Study arms Design/sample size Results
Primary end-point
Secondary end-point
Gomez DR et al.
J Clin. Oncol. 2019
37:1558e65 [27]
NSCLC
 3 metastases without PD
after3 cycles 1st line
systemic Rx
 SBRT or Surgery
to all metastatic sites
 Maintenance therapy
or observation
Randomised phase II/49 PFS 14.2 vs 4.4 mo;
p Z .022
OS 41.2 vs 17 mo;
p Z .017
Iyengar P et al. JAMA
Oncol. 2018, 4:e173501
[28]
NSCLC
 5 metastases
(plus primary)
PR or SD after
induction chemo
 SBRT to all metastatic
sites followed by
maintenance chemo
 Maintenance chemo
Randomised Phase II/29 PFS 9.7 vs 3.5 mo;
p Z .01).
Ost P et al. J Clin Oncol
2018, 36:446e453 [29]
Prostate cancer with
asymptomatic first
recurrence. No
prior therapy
 3 metastases
SBRT to all
metastatic sites
Observation
Randomised phase II/62 Androgen deprivation
free survival
21 vs 13 mo; p Z .11
Palma DA et al, Lancet.
2019; 393:2051e8 [30]
Metastatic solid
tumour
 5 metastases
 SBRT to all metastatic
sites plus standard
of care
 Standard of care
Randomised phase II/99 OS 41 vs 28 mo;
p Z $09. (NB: 3
treatment-related deaths
in SBRT arm)
OSZ overall survival; PFSZ progression-free survival; SBRTZ stereotactic (ablative) body radiation therapy; PDZ progressive disease; PRZ
partial response; SD Z Stable Disease; NSCLC Z Non Small Cell Lung Cancer.
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McCarthy in the 1950s and the inventor of the computer
programming language Lisp. AI has evolved tremen-
dously from the days of Lisp into modern Python pro-
gramming offered by major high-tech companies. AI is
generally data driven and requires input of large data
sets and is the computational vehicle for big data ana-
lytics [18]. Modern data science covers both big data, as
well as AI including machine learning algorithms and its
latest advances represented by deep learning algorithms
[19].
There are two potential areas highlighted where AI
could significantly impact the practice of radiation
oncology.
 The first is in the practical aspects of radiation planning and
delivery. For example, image analysis can be used for
tumour/normal tissue segmentation and treatment plans
can be developed based on models build on prior treatment
plans thus liberating radiation personnel from time-
consuming tasks around the image segmentation and
planning processes.
 The second and related area is in the use of such systems to
provide review and quality assurance (RTQA) of treatment
plans performed in more traditional ways and to provide
remote services for RTQA.
There are of course also important research oppor-
tunities for use of AI and deep learning algorithms most
significantly for modelling [20,21] but also for the
analysis of large clinical, biological or radiomics data
sets.
While no specific plans for clinical research questions
examining AI outputs were developed during the Stateof Science meeting, some directions were discussed as
important for clinical research groups such as the
EORTC. These groups are ideally placed to focus on
generating new potential AI applications from their
research data sets and also validating AI applications
from other groups and commercial entities on their in-
dependent data sets.
5. Targeting oligometastatic disease e who can we cure?
5.1. Current state
Metastases account for most cancer-related mortality.
Despite advances in systemic therapy, the therapeutic
approach most widely applied in this cancer stage, most
patients with metastases from solid tumours are still
considered incurable. Historically, localised modalities
such as surgical resection and radiation were generally
used with palliative intent. However, in the last two
decades, it has been hypothesised that some patients
may have truly limited (oligometastatic) tumour spread
or tumour with limited capacity to spread and that such
patients might be cured or have survival extended
through ablative approaches (radiation or surgery) to
the metastatic site(s) [22].
To date, while there is no universally accepted defi-
nition of what constitutes ‘oligometastatic’ disease,
several parallel developments in the last few years have
led to the rapid expansion of study and use of ablative
therapy for apparent oligometastatic disease. These de-
velopments include improved imaging modalities
allowing earlier and more accurate detection of metas-
tasis with lower tumour burden [23e25], as well as the
Table 4
Randomized phase III trials evaluating SBRT in addition to standard of care.
Tumour type Study arms Design Sample size Primary end-point
NCT02685397 Castrate-resistant
prostate cancer
 5 metastases
 SBRT to all
metastatic sites þ LHRH
agonist þ enzalutamide
 LHRH agonist þ enzalutamide
Phase II/III 130 (ph II)
374 (ph III)
PFS
NCT02089100 First-line metastatic
breast cancer;
 5 metastases
 SBRT to all metastatic sites
þ systemic therapy
 Systemic therapy
Phase III 280 PFS
NCT03784755 Hormone-sensitive
prostate cancer
 5 metastases
 SBRT to all metastatic sites
and untreated primary if
present þ standard
systemic therapy
 SBRT to untreated primary
if present
þ standard systemic therapy
Phase III 410 Failure-free
Survival
NCT02759783
(CORE trial)
Prostate cancer Breast
cancer NSCLC
 3 metastases
 SBRT to all metastases þ
standard of care
 Standard of care
Phase II/III 230 (ph II)
TBD (ph
III) for each
tumour type
PFS (ph II)
NCT02364557 Breast cancer
 4 metastases
 SBRT or surgery to all
metastatic sites þ standard of care
 Standard of care
Phase II/III 402 PFS (ph II)
OS (ph III)
NCT03862911 Oligometastases (1e3)  SBRT to all metastases
þ standard of care
 Standard of care
Phase III 297 OS
NCT04115007 Hormone-sensitive
prostate cancer
 5 metastases
 SBRT to all metastases
þ standard of care
 Standard of care
Phase III 350 Castrate-resistant
prostate cancer
free survival
NCT03721341 Oligometastases (4e10)  SBRT to all metastases
þ standard of care
 Standard of care
Phase III 159 OS
NCT02893332 EGFR-mutated
metastatic NSCLC
5 metastases
 SBRT to all metastases þ TKI
 TKI
Phase III 200 PFS
OS Z overall survival; PFS Z progression-free survival; SBRT Z stereotactic (ablative) body radiation therapy; TKI Z tyrosine kinase inhibitor; EGFR Z Epidermal Growth Factor; LHRH
Z luteinizing hormone-releasing hormone; NSCLC Z Non Small Cell Lung Cancer.
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dose/ablative therapy using SBRT, allowing focused
high dose radiation treatment with fewer side-effects
[26], as well as seamless integration into systemic
therapies.
Several small phase II randomised trials have been
reported in the oligometastatic setting, signalling bene-
fits in outcomes meriting further evaluation (Table 3)
[27e31].
Along with these developments, despite the lack of
any adequately powered phase III randomised studies
showing survival benefits, some guidelines have been
modified to recommend ablative therapies for oligome-
tastatic disease (defined variably) in several cancer types
(e.g. colorectal cancer, sarcoma, non-small cell lung
cancer, renal cell cancer, prostate cancer, germ cell
cancer and some paediatric cancers and breast cancer)
[32,33]. As a result, the use of radical local treatment for
oligometastases using SBRT has increased markedly. A
worldwide survey conducted in more than 1000 radia-
tion oncologists reported that more than 60% of all re-
sponders were already offering SBRT for
oligometastatic disease [34].
The increasing use of SBRT for this indication in
practice settings makes designing trials to definitively
document the potential benefits of radical treatment of
limited metastatic disease a complex problem [35].
Adding to this complexity is that fact that the spectrum
of oligometastases is broad and diverse in terms of
cancer type, biology, timing of development, previous
treatments for the primary cancer, imaging used for
detection of oligometastases and the number, location
and size of oligometastatic lesions [36]. Clinical trials
evaluating ablative therapy must in addition consider
the integration of local treatment into a systemic treat-
ment strategy. The optimal choice of radiation dose/
fractionation for radical local treatment is also un-
known, and finally relevant clinical end-points need
agreement and definition. For example, the use of the
proximal end-point of progression-free survival is
problematic when clearly patients whose disease is un-
treated will have progression detected earlier than those
whose disease is ablated. The real question is whether
such treatment changes the ultimate trajectory of disease
and impacts overall survival. Finally, the impact of
adoption of this as a standard of care could have wide
ranging impact on surveillance protocols of potentially
curatively treated patients. If it is believed early diag-
nosis and treatment of oligometastatic disease is stan-
dard, new follow-up protocols will need evaluation that
could have impacts on cancer care costs and patient
burden. Fortunately, several randomised phase III trials
are ongoing (examples shown in Table 4, identified
through a search in Clinicaltrials.gov database) and so
some of these questions will be addressed.5.2. Discussion and priority questions
While it was acknowledged that phase III evidence was
currently lacking and would be required to address some
of the uncertainties noted, some of radiation oncologists
participating in the State of Science meeting were un-
comfortable with randomising patients to standard of
care vs. ablative therapy for tumours in which guidelines
were already changing (e.g. breast, prostate, colorectal
cancer). These were however the following research
priorities identified:
i. For groups and institutions willing and able to do so,
collaboration with planned/ongoing randomised phase
III trials of oligometastatic disease in common solid
tumours is encouraged to ensure these are completed
rapidly and answers to questions about impact on sur-
vival, which patient groups are most likely to benefit are
addressed.
ii. For less common solid tumours, basket-type trials
evaluating the impact of ablative oligometastatic treat-
ments would be of value.
iii. For patients not enrolled on prospective trials, priority
should be given to registering patients undergoing oli-
gometastatic radiation therapy on the OligoCare plat-
form of E2RADIatE, developed by the EORTC-ESTRO
Radiation Infrastructure for Europe. This pragmatic
observational pan-European cohort will accumulate
data on patients undergoing radiation to oligometastatic
disease as part of their treatment trajectory and allow
assessment of factors affecting their selection for treat-
ment and their overall survival, patterns of care and
patterns of outcomes
iv. Economic analyses will be critical to include in any
prospective trials of oligometastatic SBRT, particularly
the impact of enhanced surveillance for the early
detection of small burden metastatic disease, and its
response assessment to ablative radiation therapy that
would be a consequence of adopting this approach as a
standard of care.
6. Combining radiotherapy with novel agents
6.1. Current state
The use of concurrent systemic therapy e notably
standard antineoplastic chemotherapy e in combination
with radiation has been the subject of many years of
study and is now part of the standard of care in multiple
tumour types.
While there is substantial interest in evaluating novel
agents (e.g. targeted therapies, immune oncology drugs) in
combination with radiation, there is debate about the best
preclinical models, dosing and schedule information on
which to base subsequent clinical trials. Furthermore,
there are complexities in defining the optimal clinical set-
tings in which to conduct combination studies, how to
Table 5
Clinical priorities and clinical trials in radiation oncology e consolidated recommendations.
Clinical priority Objectives Type of tumour of interest Trial design
Biology optimisation
for more
precision
Improve local
control
Nonesmall cell lung
cancer, HPV e head
and neck cancer
Locally advanced
prostate cancer,
oesophageal cancer
Endometrial Cancer
Randomisation between
standard treatment and
allocation based on radiation
sensitivity index or
hypoxia markers
Patient selection for
chemoradiotherapy
vs surgery
Muscle invasive bladder
cancer, locally advanced
rectal cancer, head
and neck cancer
Allocation of patients or
chemoradiation based on
radiation sensitivity
index to surgery
New technologies
for better
care (particles)
Reduction of
morbidity
Head and neck cancer,
endometrial cancer,
low-grade glioma
NTCP: model prediction
through cohorts followed by
trials for predicted
reduction in toxicity
Improving tumour
control without
increasing normal
tissue toxicities
Oesophageal cancer,
glioblastoma
HPV e head and
neck cancer sarcoma
Chordoma
Standard of care vs
escalating proton dosing
Artificial intelligence
to benefit
patients
Improving precision
of radiation delivery
As applicable Embedding validation of
AI on clinical trials
Monitoring quality
assurance
As applicable
Oligometastatic
patients:
improving cure
Assessing the impact
of ablative treatment
Rare solid tumours Basket trial
Other tumours Prospective registry to
document patterns of
care and outcome
Novel agents
combination
The added value of
combination with
mechanism-based agents
(IO, targeted agents.)
Rectal cancer,
oesophageal cancer
Window of opportunity
in the neoadjuvant setting
NTCP, normal tissue complication probability; AI, artificial intelligence; IO, Immuno-Oncology.
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effects may be seen) and the key intermediate efficacy end-
points which can determine if new combinations warrant
randomised evaluation. A final hurdle is that trials of new
drugs in combination with radiation are often of little in-
terest to pharmaceutical industry, meaning access to such
drugs (even for academic groups that can fund the work)
has been a challenge. Nevertheless, the State of Science
attendees highlighted the importance of developing novel
combinations with radiation, with a goal of improving
cancer outcome.
Immunotherapy was the therapeutic class of greatest
interest to pursue by those attending the State of Science
meeting. Immune-based cancer treatments have been
studied for decades, but it is only the last few years that
progress has been made in identifying new agents (e.g.
anti-CTLA4 antibodies, and PD1/PDL1 targeted
agents) of substantial clinical impact. Despite these
agents being relative newcomers to the clinic, numerous
preclinical studies have shown combining these drugswith radiation might yield synergistic effects [37]. The
theoretical mechanisms for this are several including but
not limited to the following: radiation-induced cell
damage may expose tumour antigens that may lead to
cytotoxic T-cell activation [38] and radiation-induced
changes to the microenvironment may facilitate infil-
tration of immune cells. Such preclinical information
provides a compelling rationale for combining radiation
with immune oncology agents.6.2. Discussion and priority questions
There was general agreement that phase I and II combi-
nation trials of immunotherapy and radiation should be
‘window of opportunity’ designs in locally advanced can-
cers where neoadjuvant (chemo)radiation followed by
surgery is a general standard and where early end-points
such as pathological complete response would be available
as suitable end-points on which to make decisions about
further development. In addition, where pathological
G. Thomas et al. / European Journal of Cancer 131 (2020) 76e88 85response rates may be significantly increased, avoidance of
surgery might be considered an end-point of value.
Another advantage to studying combination treatment in
this setting is that pre- and post-treatment tissue samples
could be studied to document changes in biologicmeasures
relevant to radiation sensitivity. Pre- and post-treatment
imaging could also be incorporated. Such studies could
use an ‘addition’ or ‘substitution’ design wherein the novel
agent could be either added to current therapy or
substituted for standard systemic chemotherapy given in
combination with radiation, which would be selected
would depend on the clinical context and strength of the
(preclinical) science.
Rectal cancer was identified as an optimal model.
Discussions focused on developing a platform to study
multiple questions (different drugs, doses, radiation
prescription) in a series of non-randomised sequential
trials; selecting one or more promising regimens for
phase III comparisons. Alternatively, innovative adap-
tive designs may be used advantageously to compare
several combinations across several arms of the same
trial, allowing the best arm according to the efficacy to
be enriched.
There was overlap noted with discussions in the
radiobiology session where the choice of optimal
radiotherapy for combined studies would use validated
predictive markers. The attendees felt it might be effi-
cient to incorporate this concept into combined mo-
dality studies of novel agents.7. Conclusions: where do we go from here?
Demonstrating evidence for changing practice in
cancer medicine needs clear questions, robust method-
ology and end-points and committed clinical re-
searchers. Therapeutic progress should be the result of
identifying and solving key public health questions. In
oncology multi-disciplinarity, optimising not only sys-
temic and locoregional treatments but also translational
disciplines is central to patient management. In the era
of precision oncology, biomarkers and constantly
evolving technology, solid evidence for
treatment options need a thorough assessment of high-
quality complex data sets. Efficient access to patients
alongside new solutions for clinical research needs con-
stant adaptation to the changing environment. The first
objective through the evaluation of the State of Science
in radiation oncology was to identify priorities for
clinical trials while assessing the integration of new
technologies including AI and translational science. The
second objective was to identify solutions and clinical
trials which would integrate the multi-dimensional
complexity of data to deliver evidence for these clinical
priorities (Table 5). It demonstrated that it needsinternational cooperation and cross-cutting science to
define the scientific strategy, reform approaches to data
handling and re-engineer the process of cooperation
integrating all required expertise. To improve the ther-
apeutic ratio for patients whose therapy includes radi-
ation treatment, the priorities have been identified as
optimising combination therapies with emerging sys-
temic treatments, understanding the role of particle
therapy, refining dose fractionation and dose delivery
and integrating tumour and normal tissue biology and
incorporating strategies that use AI. The European
EORTC-ESTRO Radiation Infrastructure for Europe
E2RADIatE is a pan European registry which integrates
specific cohorts for oligometastatic patients and patient
treated with protons, based on which prospective clin-
ical trials are being developed to address some of these
public health questions. Delivering evidence to improve
survival and quality of life of patients with cancer is at
the heart of such initiative and central to the mission of
such State of Science exercise. The major identified risk
is the sustainability for such independent platform,
which can only succeed if it offers ease of use and a
substantial added value to the community, willing
therefore to stimulate and support its use. Governments
and supranational funding agencies should support such
initiative and align in the best interest of patients and
society, establishing therapeutic strategies which truly
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